The potential protective role of oral anticoagulant therapy in covid-19 patients
- Journal of Cardiology & Current Research
Pasqualetto Maria Cristina, Secco Eleonora, Nizzetto Manuele, Oliboni Giancarlo, Scevola Moreno, Cester Alberto, Altafini Lorella, Graceffa Fabio, Pellegrini Andrea, Rigo Fausto
PDF Full Text
The COVID-19 pandemic is known to cause pneumonia with heterogeneous symptoms such as fever, cough and dyspnoea but also inducing systemic side effects such as a coagulopathy disorders up to serious complications due to systemic and pulmonary artery thrombosis. This phenomenon is probably due to host immune response and in particular to endothelial damage. In a full COVID19 hospital in Venice Italy, we evaluated retrospectively some clinical characteristics of the patients infected by the coronavirus (SARS-Cov-19). Our preliminary observations revealed a favourable relationship between the oral anticoagulation (OAC) therapy before the admission and a positive outcome. In fact, only a very small number of patients in therapy with OAC were admitted to our semi-intensive care department, suggesting the potentially protective role of this treatment against fatal thrombotic complications.
COVID-19, D-dimer, oral anticoagulant, pulmonary artery thrombosis, prognosis, SARS-Cov-2, microthrombosis, artery hypertension, heparin, fever, cough, dyspnoea